ASLAN Pharmaceuticals today announced the resumption of patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis.
For more information, please refer to the English or Chinese press release.